Siddhi Mahatole

Washington, D.C., United States

Correspondent at Reuters

Articles

US House committee seeks testimony from 23andMe co-founder after bankruptcy

1 week ago | today.westlaw.com | Siddhi Mahatole |Leroy Leo

(Reuters) - A U.S. House committee on Tuesday asked 23andMe's co-founder to testify next month as it launched an investigation into the risk of genetic data being transferred to potential buyers amid the DNA testing company's bankruptcy.
US FDA approves Amgen's Uplizna as first treatment for rare immune disorder

2 weeks ago | marketscreener.com | Deena Beasley |Mariam Sunny |Siddhi Mahatole

(Reuters) -The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares in patients with a rare immune system-related condition, the regulator said on Thursday.
US FDA approves Amgen's Uplizna as first treatment for rare immune disorder

2 weeks ago | streetinsider.com | Deena Beasley |Mariam Sunny |Siddhi Mahatole

1. SPY2. RH3. TSLA4. AAPL5. LCID6. RXST7. BAC8. QQQ9. LNW10. NKE Tweet Share E-mail0 shares FILE PHOTO: An Amgen sign is seen at the company's headquarters in Thousand Oaks, California, U.S., November 6, 2019.
US FDA approves Amgen's Uplizna as first treatment for rare immune disorder

2 weeks ago | sg.finance.yahoo.com | Deena Beasley |Mariam Sunny |Siddhi Mahatole

Deena Beasley, Mariam Sunny and Siddhi Mahatole Thu, 3 April 2025 at 11:49 am GMT-7 2 min read In this article: By Deena Beasley, Mariam Sunny and Siddhi Mahatole (Reuters) -The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares in patients with a rare immune system-related condition, the regulator said on Thursday.
US FDA Approves Amgen's Uplizna as First Treatment for Rare Immune Disorder

2 weeks ago | money.usnews.com | Deena Beasley |Mariam Sunny |Siddhi Mahatole

By Deena Beasley, Mariam Sunny and Siddhi Mahatole(Reuters) -The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares in patients with a rare immune system-related condition, the regulator said on Thursday.
FDA Declines Cardamyst Approval Request

3 weeks ago | conexiant.com | Siddhi Mahatole |Puyaan Singh

Milestone Pharmaceuticals announced that the FDA has declined to approve its new drug application for etripamil nasal spray (Cardamyst) to treat paroxysmal supraventricular tachycardia. In a complete response letter, the FDA cited two chemistry, manufacturing, and control issues and requested an inspection of the facility responsible for release testing. The agency also requested additional data on nitrosamine impurities, referencing guidance issued after the application was submitted.
US FDA declines to approve Milestone's heart rhythm nasal spray; shares halve

3 weeks ago | today.westlaw.com | Puyaan Singh |Siddhi Mahatole |Shreya Biswas |Shailesh Kuber

(Reuters) -Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of heart condition and had called for an inspection of the facility that performs the testing of the drug.
Consumers urged to delete 23andMe data as bankruptcy sparks privacy concerns

4 weeks ago | unionleader.com | Bhanvi Satija |Siddhi Mahatole

New York Attorney General Letitia James on Tuesday urged 23andMe customers to secure their data in light of rising privacy concerns after the DNA testing firm filed for bankruptcy amid declining demand for its services. Uncertainty surrounding the company's future and worries about potential data management by a new owner drove users to delete their accounts as a final privacy safeguard, with many taking to social media to share detailed instructions.
New York AG Letitia James urges 23andMe users to delete accounts as bankruptcy fuels privacy concerns

4 weeks ago | theglobeandmail.com | Bhanvi Satija |Siddhi Mahatole
New York AG urges 23andMe users to delete accounts as bankruptcy fuels privacy concerns

4 weeks ago | uk.marketscreener.com | Bhanvi Satija |Siddhi Mahatole

(Reuters) -New York Attorney General Letitia James on Tuesday urged 23andMe customers to delete their accounts and secure their data, days after the company filed for bankruptcy amid weak demand for its ancestry testing kits. Several users attempted to delete their accounts in a last-ditch effort to protect their privacy due to uncertainty around the company's future and what any new owner could do with user data.